Cara Therapeutics Obtains $15,000,000 Series D Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9ef83f70-8d4a-4cda-bc42-5120615911cd&Preview=1 - Date
7/21/2010 - Company Name
Cara Therapeutics - Mailing Address
One Parrott Drive Shelton, CT 06484 - Company Description
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara’s first patented compound, CR665, has entered clinical testing for acute pain. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. - Website
http://www.caratherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$15,000,000 - Transaction Round
Series D - Proceeds Purposes
The Series D financing will be used primarily for the continued clinical development of Cara’s lead peripherally restricted kappa opioid agonist, CR845, for the treatment of post-operative pain. - M&A Terms
- Venture Investor
Rho Ventures - Venture Investor
Alta Partners - Venture Investor
Devon Park Bioventures - Venture Investor
MVM Life Science Partners
